Site search

JP
EN

Top
Company Profile
Science
- About iPS-NKT
Pipeline
- Overview
- BP2201
- BP2301
- BP1200
- BP1202
- BP1210
- BP1212
- GRN-1201
- BP1209
Presentations
News
Investor Relations

News & Events

2018

ALL IR News PR

2018.12.19NewsUniversity of Tokyo and BrightPath Conclude Collaborative Research Agreement for Fully Personalized Cancer Immunotherapy（167KB）
2018.11.9IRFinancial Results for the Second Quarter of the Fiscal Year Ending March 31, 2019 [Japanese GAAP] (Consolidated)（162 KB）
2018.10.12IRAnnouncement on Dissolution of a Subsidiary（324KB）
2018.10.12IRAnnouncement on Resignation of a Director（341KB）
2018.8.10IRAnnouncement of Recognition of Extraordinary Loss (Impairment Loss)（272KB）
2018.8.10IRFinancial Results for the First Quarter of the Fiscal Year Ending March 31, 2019 [Japanese GAAP] (Consolidated)（143KB）
2018.5.17IRAnnouncement on the Results of the Phase III Clinical Trial for Cancer Peptide Vaccine ITK-1 in Patients in Japan with Prostate Cancer（276KB）
2018.5.11IRAnnouncement of Candidate for Director（128KB）
2018.5.11IRFinancial Results for the Fiscal Year ended March 31, 2018 [Japanese GAAP] (Consolidated)（505KB）
2018.3.29IRCollaborative research agreement concluded with RIKEN on iPS cell-derived NKT cell therapy（801KB）
2018.2.15NewsMie University and BrightPath Launch New Program for Neoantigen-based Personalized Cancer Immunotherapy（187KB）
2018.2.14IRFinancial Results for the Third Quarter of the Fiscal Year Ending March 31, 2018 [Japanese GAAP] (Consolidated)（395KB）
2018.1.25NewsBrightPath concludes agreement to develop personalized cancer vaccine（322KB）

2018.11.9IRFinancial Results for the Second Quarter of the Fiscal Year Ending March 31, 2019 [Japanese GAAP] (Consolidated)（162 KB）
2018.10.12IRAnnouncement on Dissolution of a Subsidiary（324KB）
2018.10.12IRAnnouncement on Resignation of a Director（341KB）
2018.8.10IRAnnouncement of Recognition of Extraordinary Loss (Impairment Loss)（272KB）
2018.8.10IRFinancial Results for the First Quarter of the Fiscal Year Ending March 31, 2019 [Japanese GAAP] (Consolidated)（143KB）
2018.5.17IRAnnouncement on the Results of the Phase III Clinical Trial for Cancer Peptide Vaccine ITK-1 in Patients in Japan with Prostate Cancer（276KB）
2018.5.11IRAnnouncement of Candidate for Director（128KB）
2018.5.11IRFinancial Results for the Fiscal Year ended March 31, 2018 [Japanese GAAP] (Consolidated)（505KB）
2018.3.29IRCollaborative research agreement concluded with RIKEN on iPS cell-derived NKT cell therapy（801KB）
2018.2.14IRFinancial Results for the Third Quarter of the Fiscal Year Ending March 31, 2018 [Japanese GAAP] (Consolidated)（395KB）

2018.12.19NewsUniversity of Tokyo and BrightPath Conclude Collaborative Research Agreement for Fully Personalized Cancer Immunotherapy（167KB）
2018.2.15NewsMie University and BrightPath Launch New Program for Neoantigen-based Personalized Cancer Immunotherapy（187KB）
2018.1.25NewsBrightPath concludes agreement to develop personalized cancer vaccine（322KB）